- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 49 Author: Unibest Industrial Publish Time: 2024-11-25 Origin: Site
Report generated for the week of 2024-11-25 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 3 drugs in the patent and exclusivity list. They are:
- ABBVIE INC's ACULAR LS, containing active ingredient KETOROLAC TROMETHAMINE
- FRESENIUS KABI USA LLC's DIPRIVAN, containing active ingredient PROPOFOL
- GLOBAL BLOOD THERAPEUTICS INC's OXBRYTA, containing active ingredient VOXELOTOR
From ABBVIE INC; as an NSAID for treating moderate to severe pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, and headaches.
Approved in May 30, 2003, used as Reference Listed Drug and Reference Standard
There are 2 future patent(s) for this application. The earliest expires on 2027-05-24, and the latest expires on 2027-11-24.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 8541463*PED | NaN | NaN | 2024-11-28 |
| 8377982*PED | NaN | NaN | 2024-11-28 |
| 8207215*PED | NaN | NaN | 2024-11-28 |
From FRESENIUS KABI USA LLC; for general anesthesia and for sedation.
Approved in Jun 11, 1996, used as Reference Listed Drug and Reference Standard
There are 1 future patent(s) for this application. The earliest expires on 2025-06-01, and the latest expires on 2025-06-01.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 8476010 | NaN | NaN | 2024-12-01 |
From GLOBAL BLOOD THERAPEUTICS INC; for treating sickle cell disease.
Approved in Dec 17, 2021, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2028-12-17, and the latest expires on 2028-12-17.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-25 | NEW CHEMICAL ENTITY |
From GLOBAL BLOOD THERAPEUTICS INC; for treating sickle cell disease.
Approved in Oct 14, 2022, used as Reference Listed Drug
There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-11-25, and the latest expires on 2028-12-17.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-25 | NEW CHEMICAL ENTITY |
Approved in Nov 25, 2019, used as Reference Listed Drug and Reference Standard
There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-11-25, and the latest expires on 2028-12-17.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-25 | NEW CHEMICAL ENTITY |
